2 results
DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A.
Primary objectives:To assess the proportion of non-severe hemophilia A patients within FVIII target levels with the DDAVP and FVIII concentrate combination treatment in the first 72 hours after the start of combination treatment, without adding off-…
Approved WMOPending
Primary:• Progression-free survival (PFS) of unesbulin plus dacarbazine (DTIC) versus placebo plus DTICSecondary:Efficacy:• Overall survival (OS) of subjects treated with unesbulin plus DTIC versus placebo plus DTIC• Antitumor activity of unesbulin…